RESUMEN
Surgical treatment of primary and recurrent volar radial wrist-forearm ganglia has yielded higher recurrence rates of ganglia when compared to surgical treatment of dorsal wrist ganglia. The published surgical literature hypothesizes that the variability in etiology of volar radial wrist-forearm ganglia may account for the higher surgical recurrence rates of these ganglia. Currently, the literature states that volar radial wrist-forearm ganglia may be secondary to arthritic intercarpal joints, carpal interosseous ganglia, or by mechanical stress within tendon sheaths, joint capsules, and ligaments. The literature has not reported pathology isolated to the flexor carpi radialis tendon and its tendon sheath at the volar trapezial fibro-osseous synovial sheath tunnel as a cause of volar radial wrist-forearm ganglia. This case series reports findings of pathology isolated to the flexor carpi radialis tendon at the trapezial fibro-osseous synovial sheath tunnel that caused primary and recurrent volar radial wrist-forearm ganglia. The pathology identified in this case series hypothesizes an additional etiologic factor in development of volar radial wrist-forearm ganglia. Surgeon awareness of potential pathology of the flexor carpi radialis tendon at the trapezial fibro-osseous synovial sheath tunnel may reduce recurrence rates of volar radial wrist-forearm ganglia treated by surgical intervention.
RESUMEN
BACKGROUND: The Par complex - comprising partition-defective 6 (Par6), Par3, and atypical protein kinase C (aPKC) - is crucial for cell polarisation, the loss of which contributes to cancer progression. Transforming growth factor ß (TGFß)-induced phosphorylation of Par6 on the conserved serine 345 is implicated in epithelial-to-mesenchymal transition (EMT) in breast cancer. Here we investigated the importance of phosphorylated Par6 in prostate cancer. METHODS: We generated a p-Par6(345)-specific antibody and verified its specificity in vitro. Endogenous p-Par6(345) was analysed by immunoblotting in normal human prostate RWPE1 and prostate cancer (PC-3U) cells. Subcellular localisation of p-Par6(345) in migrating TGFß-treated PC-3U cells was analysed by confocal imaging. Invasion assays of TGFß-treated PC-3U cells were performed. p-Par6 expression was immunohistochemically analysed in prostate cancer tissues. RESULTS: TGFß induced Par6 phosphorylation on Ser345 and its recruitment to the leading edge of the membrane ruffle in migrating PC-3U cells, where it colocalised with aPKCζ. The p-Par6-aPKCζ complex is important for cell migration and invasion, as interference with this complex prevented prostate cancer cell invasion. High levels of activated Par6 correlated with aggressive prostate cancer. CONCLUSIONS: Increased p-Par6Ser(345) levels in aggressive prostate cancer tissues and cells suggest that it could be a useful novel biomarker for predicting prostate cancer progression.
Asunto(s)
Proteínas Adaptadoras Transductoras de Señales/metabolismo , Movimiento Celular/fisiología , Neoplasias de la Próstata/metabolismo , Neoplasias de la Próstata/patología , Factor de Crecimiento Transformador beta/metabolismo , Línea Celular Tumoral , Estudios de Cohortes , Humanos , Masculino , Invasividad Neoplásica , Fosforilación , TransfecciónRESUMEN
2-methoxyestradiol (2-ME) is considered to be an effective anticancer compound for many types of tumors. We have previously demonstrated that 2-ME inhibits the growth of human cervical cancer HeLaS3 cells in vitro. In this study, we investigated the antitumoral effects of 2-ME on human cervical carcinoma in severe combined immune deficient (SCID) mice. The potential side effects of 2-ME on the SCID mice were also investigated. SCID mice were injected with HeLaS3 cells (3 x 10(6) to 4 x 10(6)/mouse) and a 15-day administration of 2-ME followed after a 1-week cell implantation. Tumor weight, volume, body weight, and blood chemistry were determined. Tumor tissues were examined with an antibody against the proliferative cell nuclear antigen and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) staining. Liver, spleen, kidney, heart, and lung were screened by pathologic examinations. 2-ME (75 mg/kg p.o.) inhibited growth of human cervical carcinoma by 34% (P < 0.05) as compared with control. Necrosis was found in both 2-ME-treated and untreated tumor tissues, but the necrotic area was larger in 2-ME-treated mice. A low expression of proliferative cell nuclear antigen and an increased number of apoptotic cells were found in 2-ME-treated tumor sections as compared to those in controls. No significant difference was detected in blood chemistry. In addition, the liver showed hyperplastic Kupffer cells, hydropic swelling of hepatocytes, and liquefactive necrosis. The spleen showed an increased number of megakaryocytes and apoptotic cells after 2-ME treatment. Thus, 2-ME has an antitumor effect on human cervical carcinoma, and it is toxic to liver and spleen in this mouse model.
Asunto(s)
Estradiol/análogos & derivados , Estradiol/farmacología , Neoplasias del Cuello Uterino/patología , 2-Metoxiestradiol , Animales , Estradiol/toxicidad , Femenino , Células HeLa , Humanos , Hígado/efectos de los fármacos , Hígado/patología , Ratones , Ratones SCID , Antígeno Nuclear de Célula en Proliferación/biosíntesis , Bazo/efectos de los fármacos , Bazo/patología , Trasplante Heterólogo , Neoplasias del Cuello Uterino/veterinariaRESUMEN
Smad proteins are major components in the intracellular signaling pathway of transforming growth factor-beta (TGF-beta), and phosphorylation is an important mechanism in regulation of their functions. Smad7 was identified as a potent inhibitor of TGF-beta-dependent signaling. We have identified serine 249 in Smad7 as a major phosphorylation site, the phosphorylation of which was not affected by TGF-beta1. Abrogation of the phosphorylation by substitution of Ser-249 with alanine or aspartic acid residues did not affect the ability of Smad7 to inhibit TGF-beta1 and BMP7 signaling. No differences were found in the stability or in the intracellular distribution of Smad7 mutants compared with the wild-type molecule. However, Smad7 fused to the DNA-binding domain of GAL4 induced transcription from a reporter with mutated TATA minimal promoter in a Ser-249-dependent manner. Moreover, a reporter with the SV40 minimal promoter was inhibited by GAL4-Smad7, and this effect was also dependent on Ser-249 phosphorylation. The amplitude of effects on transcriptional regulation was dependent on cell type. Our results suggest that phosphorylation of Smad7, unlike phosphorylation of the receptor-regulated Smads, does not regulate TGF-beta signaling but rather affects TGF-beta-independent effects of Smad7 on transcriptional regulation.
Asunto(s)
Proteínas de Unión al ADN/metabolismo , Proteínas de Unión al ADN/fisiología , Transducción de Señal , Transactivadores/metabolismo , Transactivadores/fisiología , Activación Transcripcional , Factor de Crecimiento Transformador beta/metabolismo , Células 3T3 , Secuencia de Aminoácidos , Animales , Ácido Aspártico/química , Proteínas Morfogenéticas Óseas/metabolismo , Células COS , Núcleo Celular/metabolismo , ADN/metabolismo , Proteínas de Unión al ADN/genética , Genes Reporteros , Ligandos , Luciferasas/metabolismo , Ratones , Microscopía Fluorescente , Datos de Secuencia Molecular , Mutación , Fosforilación , Regiones Promotoras Genéticas , Estructura Terciaria de Proteína , Serina/química , Proteína smad7 , Factores de Tiempo , Transactivadores/genética , Transcripción Genética , TransfecciónRESUMEN
Transforming growth factor beta (TGF-beta) is an important regulator of apoptosis in some cell types, but the underlying molecular mechanisms are largely unknown. TGF-beta signals through type I and type II receptors and downstream effector proteins, termed Smads. TGF-beta induces the phosphorylation of Smad2 and Smad3 (receptor-activated Smads) which associate with Smad4 and translocate to the nucleus, where they regulate gene transcription [1]. Smad7 protein is induced by TGF-beta1 and has been classified as an inhibitory Smad. Smad7 prevents phosphorylation of receptor-activated Smads, thereby inhibiting TGF-beta-induced signaling responses [1]. Smad7 expression is increased in rat prostatic epithelial cells undergoing apoptosis as a result of castration [2]. Here we have shown that TGF-beta1 treatment or ectopic expression of Smad7 in human prostatic carcinoma cells (PC-3U) induces apoptosis. Furthermore, TGF-beta1-induced apoptosis was prevented by inhibition of Smad7 expression, by antisense mRNA in stably transfected cell lines or upon transient transfection with antisense oligonucleotides in several investigated cell lines. These findings provide evidence for a new effector function for Smad7 in TGF-beta1 signaling.
Asunto(s)
Apoptosis , Proteínas de Unión al ADN/metabolismo , Transducción de Señal , Transactivadores/metabolismo , Factor de Crecimiento Transformador beta/metabolismo , Clorometilcetonas de Aminoácidos/farmacología , Inhibidores de Caspasas , Inhibidores de Cisteína Proteinasa/farmacología , Proteínas de Unión al ADN/genética , Regulación de la Expresión Génica , Humanos , Masculino , Neoplasias de la Próstata , Proteína smad7 , Transactivadores/genética , Factor de Crecimiento Transformador beta/farmacología , Células Tumorales CultivadasAsunto(s)
Dieta , Estrógenos no Esteroides/uso terapéutico , Isoflavonas , Neoplasias de la Próstata/prevención & control , Proteínas de Soja/uso terapéutico , Animales , Estrógenos no Esteroides/administración & dosificación , Finlandia/epidemiología , Humanos , Japón/epidemiología , Masculino , Fitoestrógenos , Preparaciones de Plantas , Neoplasias de la Próstata/epidemiología , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: The influence of tobacco smoke has been investigated on the growth rate and histology of prostate cancer, both in untreated tumors and in those subjected to fractionated irradiation. METHODS: Twenty-five rats were implanted bilaterally with Dunning R3327 tumor fragments at 10 weeks of age. Approximately 3 months later, they were randomly allocated to two groups, one of which was exposed to tobacco smoke for an hour each day, 5 days a week. Three weeks later the groups were further subdivided into two groups which acted as controls or were subjected to 5 daily doses of 6 Gy. The tumors were measured weekly to construct growth curves. At a fixed time, 9 weeks or 20 weeks later, the animals were sacrificed and the tumors were removed for histological evaluation of the tissue composition. Sections from each tumor were scored in a morphometric analysis of the fraction of the area of tumor that was occupied by (epithelial) tumor cells, by stroma, or by luminal spaces. In addition, the density of mast cells was assessed in adjacent sections stained with toluidine blue. RESULTS: Smoking caused only minor changes in the growth rates of both the control and the irradiated tumors. At the cellular level, smoking caused a small but significant increase in the fraction of tumor cells relative to controls. Irradiation also caused a small but significant decrease in tumor cell fraction compared to controls, even after 20 weeks of regrowth. This difference was reduced in the smoking and irradiation group. The main difference observed was in the mast cell numbers. Smoking caused a 4-fold increase in mast-cell density. Irradiation caused an even greater increase (25-fold). The combination of smoking and irradiation resulted in an intermediate increase (10-fold). CONCLUSIONS: Long-term smoke exposure can slightly alter the growth rate and morphology of Dunning R3327 rat prostatic adenocarcinoma, but our study does not show a negative effect on the outcome of radiation treatment of this tumor model. We have also demonstrated a highly elevated number of mast cells in the irradiated group, and have shown that smoke exposure significantly depressed the radiation-induced enhancement of the number of mast cells.
Asunto(s)
Adenocarcinoma/patología , Neoplasias de la Próstata/patología , Fumar/efectos adversos , Adenocarcinoma/radioterapia , Animales , Recuento de Células , Masculino , Mastocitos , Trasplante de Neoplasias , Plantas Tóxicas , Neoplasias de la Próstata/radioterapia , Distribución Aleatoria , Ratas , Ratas Endogámicas F344 , NicotianaRESUMEN
The present study was designed to determine whether IL-2 and histamine alone, or in combination could modulate the effects of irradiation on Dunning (R3327) rat adenocarcinomas at the cellular level. Copenhagen x Fisher rats carrying bilateral tumours in the flank were used. When the tumours had a median volume of 150 mm3, one group of rats was treated with histamine alone (4 mgkg-1 subcutaneously on week days), another group with interleukin-2 (IL-2) alone (425 IU kg-1 continuous infusion) and a third group with both histamine and IL-2 during 6 weeks. Irradiation was given one week after the onset of treatment with histamine and/or IL-2, with a linear accelerator 6 MV, in a dose of 6 Gy/day for 3 days to the tumour of one side, while the other side served as control. Morphometric analyses of the amount of cystic structures, volume density for tumour epithelium, stroma and acinar lumina, the number of activated macrophages and natural killer cells (NK-cells) and in situ detection of apoptotic cells was carried out 5 weeks after the irradiation, when the experiment was ceased. The combination of IL-2 with histamine and irradiation significantly augmented the reduction of tumour cells (p < 0.002) and increased the number of apoptotic cells (p < 0.007) compared to irradiation alone. The number of cystic structures within tumour tissue increased in all tumours that received histamine, but was most pronounced in the three combination group. A strong negative correlation between the epithelial cells and the apoptotic index (rs = -0.61, p < 0.0001) and a strong positive correlation between the stroma and the apoptotic index (rs = 0.59, p < 0.001) was found. A prominent infiltration of activated macrophages was observed in the irradiated group. This infiltration was impaired by the drugs. The results suggested that the used three modality treatment could be of value in increasing the efficacy of local radiotherapy concomitantly with a most plausible effect on micrometastatic spread. The results also propose that volume measurements alone are not an optimal parameter when evaluating effects of new treatment modalities.
Asunto(s)
Adenocarcinoma/patología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Apoptosis/efectos de los fármacos , Histamina/uso terapéutico , Factores Inmunológicos/uso terapéutico , Interleucina-2/uso terapéutico , Neoplasias de la Próstata/patología , Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/radioterapia , Animales , Protocolos de Quimioterapia Combinada Antineoplásica/administración & dosificación , Terapia Combinada , Cruzamientos Genéticos , Histamina/administración & dosificación , Histamina/farmacología , Factores Inmunológicos/administración & dosificación , Interleucina-2/administración & dosificación , Interleucina-2/farmacología , Células Asesinas Naturales/inmunología , Activación de Macrófagos , Masculino , Trasplante de Neoplasias , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Ratas , Ratas Endogámicas F344 , Células del Estroma/efectos de los fármacosRESUMEN
Escape from transforming growth factor-beta (TGF-beta)-induced inhibition of proliferation has been observed in many tumor cells and may contribute to loss of growth control. Smad proteins have been identified as major components in the intracellular signaling of TGF-beta family members. In this study, we examined the expression of receptor-activated, common-mediator and inhibitory Smads by immunohistochemistry in human colorectal cancers. We found increased expression of receptor-activated Smads in a fraction of the tumor cells, while no immunostaining for Smad2, Smad3 or Smad5 and only occasional staining for Smad1/8 was found in epithelial mucosa of normal colon. No or only weak staining for receptor-activated Smads, common-mediator Smad4 and inhibitory Smads was observed in the tumor stroma. Common-mediator Smad4 and inhibitory Smads were detected in cells of both tumor and normal tissues. We observed a distinct pattern of Smad4 immunostaining of epithelial cells along colon crypts, with high expression in zones of terminal differentiation. Our data show selective up-regulation of receptor-activated Smad proteins in human colorectal cancers and suggest involvement of Smad4 in differentiation and apoptosis of surface epithelial cells of normal crypts.
Asunto(s)
Carcinoma/metabolismo , Neoplasias Colorrectales/metabolismo , Proteínas de Unión al ADN/biosíntesis , Proteínas de Neoplasias/biosíntesis , Fosfoproteínas/biosíntesis , Transactivadores/biosíntesis , Secuencia de Aminoácidos , Antígeno Carcinoembrionario/biosíntesis , Carcinoma/genética , Neoplasias Colorrectales/genética , Proteínas de Unión al ADN/genética , Progresión de la Enfermedad , Regulación Neoplásica de la Expresión Génica , Genes APC , Genes DCC , Humanos , Etiquetado Corte-Fin in Situ , Datos de Secuencia Molecular , Proteínas de Neoplasias/genética , Fosfoproteínas/genética , Fosforilación , Procesamiento Proteico-Postraduccional , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Transducción de Señal , Proteínas Smad , Proteína Smad1 , Proteína Smad2 , Proteína smad3 , Proteína Smad5 , Proteína smad6 , Proteína smad7 , Proteína Smad8 , Transactivadores/genética , Factor de Crecimiento Transformador beta/biosíntesisRESUMEN
Transforming growth factor (TGF)-beta1 is induced in the prostate after castration and has been implicated in apoptosis of epithelial cells during involution. TGF-beta1-mediated receptor activation induces phosphorylation of Smad2 and Smad3, which form complexes with Smad4, that translocate to the nucleus to regulate transcription of target genes. Smad6 and Smad7 antagonize the action of signal-transducing Smads. We have examined the immunohistochemical expression of different Smad molecules in the epithelium of rat ventral prostate before and after castration, in androgen-sensitive Dunning R3327 PAP prostatic tumor cells from untreated and castrated rats, and after treatment with estrogen. In the ventral prostate, a significant increase of phosphorylated Smad2 (P-Smad2) was observed after castration. In prostatic tumor cells we observed an increased expression of Smad2 and P-Smad2 after treatment. The levels of Smad3 and, in particular, Smad4 were enhanced in the normal ventral prostate, as well as in the tumors after castration. Interestingly, Smad6 and Smad7 expression was also up-regulated in cells with increased Smad2 activation. The staining for Smad2, P-Smad2, Smad3, Smad4, and Smad7 was nuclear in some cells and was present in areas with a large number of apoptotic cells identified by various morphological criteria, formation of apoptotic bodies and, in adjacent sections, by terminal deoxynucleotidyl transferase-mediated nick end labeling assay. Our results suggest that the signal transduction pathway for TGF-beta, leading to apoptosis, is activated in the normal prostate after castration and in the tumor model after castration, without or with estrogen treatment.
Asunto(s)
Apoptosis/fisiología , Proteínas de Unión al ADN/metabolismo , Próstata/metabolismo , Neoplasias de la Próstata/metabolismo , Transactivadores/metabolismo , Animales , Masculino , Orquiectomía , Fosfoproteínas/metabolismo , Próstata/citología , Neoplasias de la Próstata/patología , Ratas , Ratas Sprague-Dawley , Receptores de Factores de Crecimiento Transformadores beta/metabolismo , Proteína Smad2 , Proteína smad3 , Proteína Smad4 , Proteína Smad5 , Proteína smad6 , Proteína smad7 , Factor de Crecimiento Transformador beta/metabolismoRESUMEN
Transforming growth factor beta (TGF-beta) signals from membrane to nucleus through serine/threonine kinase receptors and their downstream effector molecules, termed Smad proteins. Recently, Smad6 and Smad7 were identified, which antagonize TGF-beta family signaling by preventing the activation of signal-transducing Smad complexes. Here we report that Smad7, but not Smad6, inhibits TGF-beta1-induced growth inhibition and the expression of immediate early response genes, including Smad7. Interestingly, in the absence of ligand, Smad7 was found to be predominantly localized in the nucleus, whereas Smad7 accumulated in the cytoplasm upon TGF-beta receptor activation. The latter is in accordance with the physical association of Smad7 with the ligand-activated TGF-beta receptor complex in the cell membrane. Whereas the ectopically expressed C-terminal domain of Smad7 was also exported from the nucleus to the cytoplasm upon TGF-beta challenge, a Smad7 mutant with a small deletion at the C terminus or only the N-terminal domain of Smad7 was localized mainly in the cytoplasm in the absence or presence of ligand. This suggests that an intact Mad homology 2 domain is important for nuclear localization of Smad7. The nuclear localization of Smad7 suggests a functional role distinct from its antagonistic effect in receptor-mediated Smad activation.
Asunto(s)
Núcleo Celular/metabolismo , Proteínas de Unión al ADN/metabolismo , Transactivadores/metabolismo , Factor de Crecimiento Transformador beta/fisiología , Animales , Transporte Biológico , Células COS , División Celular/fisiología , Línea Celular , Proteínas de Unión al ADN/genética , Proteínas de Unión al ADN/fisiología , Visón , Eliminación de Secuencia , Transducción de Señal/fisiología , Proteína smad7 , Transactivadores/genética , Transactivadores/fisiología , Transcripción Genética/fisiología , Transfección , Factor de Crecimiento Transformador beta/antagonistas & inhibidoresRESUMEN
METHODS: Dunning R3327 PAP prostate tumors were transplanted in 125 rats, the rats were divided into five groups, and tumor development was examined for 24 weeks during treatment with diets containing 33% of soy flour (SD), rye bran (RB), heat-treated rye bran (HRB), or rye endosperm (RE). RESULTS: In the SD, RB, and HRB groups, significantly fewer palpable tumors and lower tumor volume were detected 14 and 16 weeks after transplantation when compared with the control, fiber-free dietary (FF) group. The body weight was lower 16 weeks after tumor transplantation in the RB and HRB groups when compared with the control group (P < 0.05). Rats in the RB and the HRB groups had a significant lower energy intake than the FF group during the first metabolic observation period, 3-6 weeks after tumor transplantation (P < 0.05), whereas the energy intake was the same in all groups during the second metabolic observation period, 13-16 weeks after tumor transplantation. However, when the tumor volume was adjusted for the body weight of the animals, there were still significant lower tumor volumes in the SD, RB, and HRB groups compared with the FF group (P < 0.05). A significant increase in daily urinary excretion of the isoflavonoids, daidzein, O-desmethylangolensin, equol, and Genistein, was observed in the rats fed SD, and of the ligands enterolactone and enterodiol in the rats fed RB and HRB during both metabolic periods. There were no differences in testosterone levels between the groups. CONCLUSIONS: The present study shows that SD inhibits implanted prostate cancer growth. Although RB and HRB had a protective effect, further studies are needed to exclude the possibility that a low energy intake played a role in this respect. The results suggest that phytoestrogens (isoflavonoids and ligands), may be responsible for the delayed prostate tumor growth.
Asunto(s)
Adenocarcinoma/fisiopatología , Dieta , Estrógenos no Esteroides/farmacología , Neoplasias de la Próstata/fisiopatología , Secale , Proteínas de Soja , Animales , Ingestión de Energía , Masculino , RatasRESUMEN
A syngeneic, androgen-sensitive Dunning R3327 rat prostatic adenocarcinoma was transplanted bilaterally in the flanks of male Copenhagen Fisher rats. Approximately 3 months after implantation, when the tumours had a median volume of 150 mm3, one group of rats was treated with histamine alone (4 mg kg(-1) subcutaneously on week days), another group with human recombinant interleukin 2 (IL-2) alone (425 IU kg(-1) continuous infusion) and a third group with both histamine and IL-2 during 6 weeks. Tumours on one flank were irradiated (6 Gy once daily for 3 days to a total dose of 18 Gy) beginning 1 week after the onset of treatment with histamine and/or IL-2. The contralateral tumour served as the intra-animal control. The tumour volumes were determined weekly. The growth curves showed that all three drug treatments were effective in delaying growth, but when used individually did not cause tumour shrinkage. Radiation was the most effective single agent, but when used alone the shrinkage did not occur until 2 weeks after irradiation. When combined with the drugs, more rapid and extensive growth delay and/or shrinkage was seen. The growth curves showed clear differences between the different treatments. The combination of the three agents was the most effective of all. The most striking difference between radiation alone and radiation plus biotherapy was the time at which a tumour response was detectable. Thus, active biotherapy alone and especially in a combination with histamine and radiotherapy warrants further investigation as a potential therapeutic approach to prostate cancer.
Asunto(s)
Adenocarcinoma/tratamiento farmacológico , Adenocarcinoma/radioterapia , Histamina/uso terapéutico , Interleucina-2/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/radioterapia , Adenocarcinoma/patología , Animales , Terapia Combinada , Quimioterapia Combinada , Humanos , Masculino , Trasplante de Neoplasias , Neoplasias de la Próstata/patología , Ratas , Proteínas Recombinantes/uso terapéutico , Células Tumorales CultivadasRESUMEN
PURPOSE: The present study using the Dunning R3327-PAP rat prostatic adenocarcinoma model was designed to study the effect on tumor growth of castration prior to or after irradiation with 20-25 Gy as compared with either irradiation or castration alone. METHODS AND MATERIALS: Rats were bilaterally orchidectomized. During the irradiation procedure the nonanesthetized animals were held in a metallic frame with a strong cotton net and they were observed by means of a video camera. The suboptimal irradiation dose was given once daily with a 4-MeV linear accelerator, 4-5 Gy/fraction, during 5 consecutive days. Tumor volumes and rat weights were followed. At the end point of the study the animals were sacrificed and the tumors were morphometrically analyzed. RESULTS: The combination of irradiation and castration delayed tumor regrowth better than irradiation alone with the same suboptimal dose. Castration before irradiation delayed tumor regrowth more efficiently than castration after irradiation. However, castration alone delayed tumor regrowth even more effectively than suboptimal irradiation doses combined with castration. CONCLUSIONS: In combination with suboptimal irradiation neoadjuvant androgen deprivation was more inhibitory to rat prostatic adenocarcinoma regrowth than adjuvant androgen deprivation. Irradiation with suboptimal doses combined with castration may cause an earlier relapse to androgen-independent tumor growth than castration alone.
Asunto(s)
Adenocarcinoma/radioterapia , Adenocarcinoma/cirugía , Orquiectomía , Neoplasias de la Próstata/radioterapia , Neoplasias de la Próstata/cirugía , Animales , Terapia Combinada , Estudios de Seguimiento , Masculino , Recurrencia Local de Neoplasia/prevención & control , Dosificación Radioterapéutica , RatasRESUMEN
Rats transplanted with the androgen-sensitive, syngeneic Dunning R3327 PAP prostatic tumor were castrated and treated with estrogen or vehicle for 4, 12 and 24 hr and for 6 weeks. Tumor growth was retarded by castration and further inhibited by estrogen. Immediately after castration, an increased number of activated macrophages and T-cells were found in parallel with increasing apoptotic tumor cells. Administration of an immunosuppressive drug, FK 506, abolished the growth-inhibitory effects of castration and estrogen. The tumor growth rate correlated negatively with the number of R73- and OX8-positive T-cells and NK cells and with the percentage of ED3-positive macrophages. There was a positive correlation between the percentage of TdT-mediated-dUTP nick end labeling (TUNEL)-positive apoptotic cells and that of ED3-positive cells. Our results suggest that apoptosis of prostatic carcinoma cells induced by endocrine treatment in vivo is partly due to a rapid infiltration by immunocompetent cells.
Asunto(s)
Adenocarcinoma/inmunología , Adenocarcinoma/patología , Apoptosis , Macrófagos/patología , Neoplasias de la Próstata/inmunología , Neoplasias de la Próstata/patología , Linfocitos T Citotóxicos/inmunología , Animales , División Celular/efectos de los fármacos , Estradiol/farmacología , Inmunosupresores/farmacología , Células Asesinas Naturales/inmunología , Células Asesinas Naturales/patología , Activación de Macrófagos , Macrófagos/inmunología , Masculino , Orquiectomía , Ratas , Tacrolimus/farmacología , Células Tumorales CultivadasRESUMEN
Two experiments were conducted to investigate the effect of soy and rye on the development of Dunning R3327 prostatic adenocarcinoma in rats.
Asunto(s)
Adenocarcinoma/prevención & control , Glycine max , Neoplasias de la Próstata/prevención & control , Secale , Animales , Peso Corporal , Ingestión de Energía , Isoflavonas/orina , Masculino , Trasplante de Neoplasias , RatasRESUMEN
Smoking is associated with the development of different malignancies, especially lung carcinoma. Considerably less interest has been devoted whether the outcome of cancer treatment can be affected by ongoing smoking. In the present study, the effects of ongoing smoking was evaluated on the expression of classical multidrug resistance (MDR-1) in a tumour tissue not usually related to smoking, prostatic carcinoma in rats. The expression of mdr1 was evaluated by quantitative RNA-RNA solution hybridisation and the distribution of the glycoprotein P-170 was examined by immunohistochemistry using the monoclonal antibodies C219 and C494. A group of animals was exposed to cigarette smoke in a nose-only exposure system for 1 h/day, 5 days/week for four weeks. The results demonstrated a significant enhanced expression of mdr1 RNA in the rumours from smoke exposed animals and the immunohistochemical analysis also displayed an increase of the positively stained cells following smoking. These results indicate that alteration at least at the level of transcription is involved in the overexpression of P-170 following smoking. An effect on translation or post-translation cannot be excluded. The observations might add to the experience of drug resistance seen in the clinical situation in tumours associated with carcinogens such as smoking.
RESUMEN
Rats transplanted with the androgen-sensitive Dunning R3327 PAP prostatic adenocarcinoma were castrated and treated with either estrogen or vehicle alone for short periods (4 hr, 12 hr, 24 hr) and for 6 weeks. In these tumors the expression of TGF-beta 1, TGF-beta type-I and type-II receptors (TGF-beta RI, TGF-beta RII) was examined by immunohistochemistry. Apoptotic cells were identified by in situ nick and labelling (TUNEL). Tumor growth was retarded by castration and even more by additive estrogen treatment. The epithelium of the untreated tumors stained weakly for TGF-beta 1 and TGF-beta RI, but TGF-beta RII was not detected. Castration induced moderate TGF-beta 1 immunoreactivity in a major part of the glandular epithelium after 24 hr. After 12 hr already, castration plus estrogen resulted in an intense staining for TGF-beta 1 in the basal epithelial cells, some of which also showed an apoptotic appearance. The percentage of cells having stained positive for TGF-beta 1 was significantly higher in the estrogen-treated groups than in the castrated group after 12 hr, and its elevated TGF-beta 1 level remained at 6 weeks. Notably, the increased immunoexpression of TGF-beta 1 occurred before the onset of induction of apoptosis. In parallel with the upregulation of TGF-beta 1 after castration, the expression of its receptors. TGF-beta RI and RII, was induced and was further enhanced by the additive estrogen treatment. The number of intensely stained TGF-beta 1 tumor cells showed a strong correlation with the number of apoptotic tumor cells identified by TUNEL in the whole material. Furthermore, TGF-beta 1 immunoreactivity co-localized with the presence of apoptotic cells in the estrogen-treated tumors at 6 weeks after castration.
Asunto(s)
Receptores de Activinas Tipo I , Adenocarcinoma/patología , Apoptosis/efectos de los fármacos , Estradiol/farmacología , Neoplasias de la Próstata/patología , Proteínas Serina-Treonina Quinasas/biosíntesis , Receptores de Factores de Crecimiento Transformadores beta/biosíntesis , Factor de Crecimiento Transformador beta/biosíntesis , Adenocarcinoma/metabolismo , Animales , División Celular/efectos de los fármacos , Expresión Génica/efectos de los fármacos , Inmunohistoquímica , Masculino , Índice Mitótico/efectos de los fármacos , Orquiectomía , Neoplasias de la Próstata/metabolismo , Ratas , Ratas Endogámicas F344 , Receptor Tipo I de Factor de Crecimiento Transformador beta , Receptor Tipo II de Factor de Crecimiento Transformador betaRESUMEN
Oncoprotein 18 (Op18) is an intracellular phosphoprotein that has been shown to be overexpression in a number of human malignancies. In the present report we have studied the pattern of Op18 expression on normal, hyperplastic, and malignant prostatic tissue as well as in rat prostatic tumor lines. One of the objectives of the present work was to establish whether the level of Op18 expression can be used as a prognostic marker in human prostatic adenocarcinoma. To that end, sections from normal, hyperplastic, and malignant human prostatic tissue were examined by immunohistochemistry for expression of Op18. In the normal and hyperplastic prostate, Op18 expression was observed in basal glandular epithelial cells, whereas the columnar luminal epithelial cells were not stained by the anti Op18 antibodies. In highly differentiated prostatic cancers occasional epithelial cells were stained, while in poorly differentiated tumors most of the epithelial cells contained Op18 immunoreactivity. The staining pattern was similar in the primary prostatic tumor and in the regional lymph node metastases. Most importantly, a limited survey of prostatic cancer patient samples (n = 40) showed a significant correlation between the fraction of Op18 immunoreactive cells and survival. Studies of a rat prostatic tumor model, showed that only a few cells were stained in the highly differentiated Dunning R3327PAP tumor, while most cells were stained in the anaplastic AT1 rat prostatic tumor. Interestingly, castration of rats resulted in an increased Op18 immunoreactivity, within 14 days, in the highly differentiated rat R3327PAP prostatic tumor. In conclusion, the level of Op18 expression seems to be related to cellular differentiation, histological grade, and survival in prostatic cancers. These findings show that Op18 immunoreactivity may be useful as a prognostic marker in prostatic cancer. In addition it may help in the differentiation between highly differentiated prostatic tumors and non-malignant conditions.
Asunto(s)
Adenocarcinoma/metabolismo , Biomarcadores de Tumor/biosíntesis , Proteínas de Microtúbulos , Fosfoproteínas/biosíntesis , Neoplasias de la Próstata/metabolismo , Adenocarcinoma/patología , Animales , Regulación Neoplásica de la Expresión Génica , Humanos , Inmunohistoquímica , Masculino , Valor Predictivo de las Pruebas , Pronóstico , Neoplasias de la Próstata/patología , Ratas , Estatmina , Análisis de SupervivenciaRESUMEN
Castration of rats transplanted with the androgen-sensitive Dunning R3327-PAP prostatic tumor results initially in a reduction of tumor growth, but after some time, some of the tumors start to grow again. The relapsed, androgen-insensitive PAP tumor shows a dedifferentiated morphology. In the present study, we examined whether this androgen-independent tumor regrowth was due to an increased cell proliferation rate or to a reduction of the number of tumor cells dying by apoptosis. Nine rats (with 18 tumors) were castrated and followed for 16 to 20 weeks. Six of the tumors increased their volume markedly (relapsed), while 12 remained relatively stable (nonrelapsed). The mitotic index and apoptotic index for epithelial cells were examined by light microscopy. Tumor growth rate correlated negatively both to the apoptotic index identified by morphological criteria (RS = -0.82; P < 0.0001) and to the apoptotic index identified by in situ end labeling (RS = -0.83; P < 0.0001). The tumor growth rate percentage did not correlate to the mitotic index, and it was negatively correlated (RS = -0.62; P < 0.01) to the number of cells immunostained for proliferating cell nuclear antigen. It is suggested that one initial event during the androgen-independent prostatic tumor regrowth in the PAP relapse model might be a reduction of the number of tumor cells being depleted by apoptosis, rather than an increase of cell proliferation rate.